Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Qatar Investment Authority
AddedFeb 11, 2024
UpdatedJul 9, 2026
Qatar Investment Authority

Qatar Investment Authority

Operating

Qatar Investment Authority: Qatar's sovereign wealth fund, diversifying assets since 2005, managing $475B.

Location
Doha, Doha, QA
Founded
2005
Firm
Compare
Portfolio
Employees
News
Website

Investments

SambaNova Systems
SambaNova Systems
Series F

Total Raised

$2.5B

Rounds

8

Series F$1BJuly 2026
HyperLight
HyperLight
Series C

Total Raised

$80M

Rounds

1

Series C$80MJune 2026
ICEYE
ICEYE
Series F

Total Raised

$963M

Rounds

7

Series F$450MJune 2026
Replit
Replit
Series D

Total Raised

$872M

Rounds

12

Series D$400MMarch 2026
Precede Biosciences
Precede Biosciences

Total Raised

$57M

Rounds

1

Series A$57MOctober 2023
BridgeBio Pharma
BridgeBio Pharma
Public

Total Raised

$3.6B

Rounds

13

Post Ipo Equity$250MSeptember 2023
Databricks
Databricks

Total Raised

$29.2B

Rounds

14

Series I$684.6MSeptember 2023
Ascend Elements
Ascend Elements

Total Raised

$1.5B

Rounds

13

Series D$460MSeptember 2023
Star Therapeutics
Star Therapeutics

Total Raised

$190M

Rounds

2

Series C$90MSeptember 2023
Reliance Retail
Reliance Retail
Public

Total Raised

$502.7B

Rounds

9

Private Equity$82.8BAugust 2023
The North Road Company
The North Road Company

Total Raised

$950M

Rounds

3

Private Equity$150MJanuary 2023
Ensoma
Ensoma

Total Raised

$205M

Rounds

3

Series B$85MJanuary 2023
Snyk
Snyk

Total Raised

$1.2B

Rounds

13

Series G$196.5MDecember 2022
Senda Biosciences
Senda Biosciences

Total Raised

$309M

Rounds

3

Series C$123MAugust 2022
BioXcel Therapeutics
BioXcel Therapeutics
Public

Total Raised

$140M

Rounds

3

Post Ipo Debt$135MApril 2022
Post Ipo Equity$5MApril 2022
Fanatics
Fanatics
Public

Total Raised

$4.9B

Rounds

11

Private Equity$1.5BMarch 2022
Ventus Therapeutics
Ventus Therapeutics

Total Raised

$370.1M

Rounds

5

Series C$140MFebruary 2022
Impact
Impact

Total Raised

$361.4M

Rounds

6

Private Equity$150MJuly 2021
Flipkart
Flipkart
Acquired Subsidiary

Total Raised

$56.1B

Rounds

28

Private Equity$3.6BJuly 2021
Age of Learning
Age of Learning

Total Raised

$531.5M

Rounds

5

Series C$300MJune 2021
Thumbtack
Thumbtack

Total Raised

$698.2M

Rounds

8

Series G$275MJune 2021
Entrada Therapeutics
Entrada Therapeutics
Public

Total Raised

$201.6M

Rounds

5

Series B$116MMarch 2021
OncoResponse
OncoResponse

Total Raised

$130.1M

Rounds

7

Series C$40.6MMarch 2021
Siemens Healthineers
Siemens Healthineers
Public

Total Raised

$2.3B

Rounds

3

Post Ipo Equity$2.3BMarch 2021